CAR T-cell Therapy Market – By Product, By Indication, By Demographic, By End Use, Global Forecast, 2025 – 2034

CAR T-cell Therapy Market Size

The global CAR T-cell therapy market size was valued at USD 4.3 billion in 2024 and is estimated to grow at 30.5% CAGR from 2025 to 2034. CAR T-cell therapy is an effective treatment for those suffering from cancer since it entails modifying the patient’s T-cells health.
 

The cells that are genetically altered possess the capability of targeting cancer cells with a greater degree of efficiency. CAR T-cell therapy means collecting T-cells from a patient, customizing them in a laboratory by changing their molecular structure with specific receptors, and inserting them back into the patient. These engineered receptors are called chimeric antigen receptors (CARs), and together with the patient T-cells, allow for better identification and destruction of cancer cells.

Rising cases of cancer across the globe is one of the primary reasons that CAR T-cell therapy is likely to see a significant rise in demand. For instance, the WHO estimates the number of new cancer cases to beyond twofold approximately 35 million in 2050, up from 20 million cases in 2022. This rise in the number of cases suggests a greater need for more innovative and effective treatments such as CAR T-cell therapy, especially for patients suffering from relapsed cancers as well as refractory cancers in order to meet the growing demand in the market.
 

Preliminary analysis suggests better approaches and more specific T-cell therapies to be in the market owing to the brilliant outcomes of gene editing technologies, especially that of CRISPR. For instance, according to a report by the American National Institutes of Health (NIH), the CRISPR/Cas9 technology is a useful tool for improving CAR T-cell expansion and persistence in vivo. Other innovations include allogeneic (off-the-shelf) CAR T-cell therapy, which could increase the addressable market by making therapies more cost-effective and increasing access. Unlike autologous CAR T-cells, these therapies do not use the patient’s own cells. All these technological improvements are important for making it possible to use CAR T-cell therapies also in other types of cancer.
 

CAR T-cell Therapy Market Trends

• Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have implemented expedited approval pathways for CAR T-cell therapies through breakthrough and orphan drug designations.
   
• The results of six CAR T-cell therapies approved by the FDA in 2023 is a good demonstration of regulatory engagement which aims fast time to market which is fundamentally crucial for patients seeking such CAR T-cell treatment modalities to gain quick access to the market.
   
•  In addition, T-cell research and clinical trials are provided considerable support by both governmental agencies and private investors. For example, in September 2023, the National Cancer Institute (NCI) awarded a grant worth USD 3.04 million over five years to Ohio State University. The purpose of this research is to develop a novel CAR T-cell therapy that addresses three targeted proteins rather than one and aims to improve the treatment of patients suffering from relapsed or treatment-resistant B cell malignancies.
   
• That amount of funding both from the public and the private sector illustrates the ability of CAR T-cell therapies to disrupt cancer treatment and sustain innovation in this area.
  
   

CAR T-cell Therapy Market Analysis

Based on product, the market is segmented into Abecma, Breyanzi, Carvykti, Kymriah, Tecartus, Yescarta, and other products. The Yescarta segment dominated the market with the largest revenue share of 32.5% in 2024.
 

• The growing number of B-cell lymphomas in conjunction with the few therapies that are available for both relapsed and refractory cases has increased the need for therapies such as Yescarta.
   
• The American Cancer Society estimates that B-cell lymphoma, a form of non-Hodgkin lymphoma, constitutes about 3.4% of cancer cases globally. This prevalence is quite high, and it has led to the development of new treatments such as Yescarta, which has been shown to be effective in controlling B-cell lymphoma.
   
• The FDA and EMA, among other regulatory bodies, have also established faster routes of approval for the use of CAR T-cell therapies. They recognize these therapies as potentially life-saving. In 2017, Yescarta was approved for use for large B-cell lymphoma and in 2021 it was approved for use for follicular lymphoma. Since that time, the indications for the use of Yescarta have significantly increased thus expanding its avenues for commercialization.

Based on indication, the CAR T-cell therapy market is segmented into leukemia, lymphoma, multiple myeloma, and other indications. The lymphoma segment dominated the market with the largest revenue of USD 2.4 billion in 2024.
 

• B-cell lymphomas, especially diffuse large B-cell lymphoma (DLBCL), are the most frequent type of non-Hodgkin lymphoma. Diffuse large B-cell lymphoma is reported to account for about 30-40% of the total cases of non-Hodgkin lymphoma worldwide according to the World Health Organization.
   
• The relapse rate of these lymphomas is high after the Olympic standard form of treatment. According to National Institutes of Health (NIH), DLBCL has a relapse rate of approximately 30-40% over two years after the first line of treatment.
   
• Encouraged demand for CAR T-cell therapies that have been particularly effective for aggressive lymphomas has been caused by the high relapse rate of B-cell lymphoma, with CAR T-cells also being able to achieve a complete response.
   

Based on demographic, the CAR T-cell therapy market is bifurcated into adults and pediatric. The adults segment dominated the market with the largest revenue share of 87.3% in 2024.
 

• There has been a spike in demand for the CAR T-cell therapy, particularly in adults and the elderly cancer patients, due to the rise in incidence of cancer among them.
   
• For instance, as per Cancer Research UK, in the UK more than 50% of the new cancer cases are registered in the age between 50 to 74 years account, while above 75 years age holders account for over 33%.
   
• All these factors are expected to contribute to the upsurge of the growth of the adult segment with innovative treatment alternatives being developed to cater to the needs of elder cancer patients.
   

Based on end use, the CAR T-cell therapy market is segmented into hospitals, cancer treatment centers, and specialty clinics. The hospitals segment dominated the market with the largest revenue of USD 2.4 billion in 2024.
 

• There is a growing trend of hospitals putting extra effort into healthcare infrastructure development, which also includes cellular therapy units to support the amalgamation and ease of access to CAR T-cell therapies.
   
• In addition, many hospitals are also making progress towards providing training to their staff and obtaining new technologies to facilitate CAR T-cell therapy, thus, making it easier for patients to use.
   
• Such infrastructure extension and technology improvement particularly allow for the more advanced implementation of CAR T-cell therapies, which in turn increases the growth of the hospitals segment.

The U.S. CAR T-cell therapy market is projected to grow significantly, reaching USD 25 billion by 2034.
 

• Breakthrough therapy designation for a few treatments has simplified the approval for CAR T-cell therapies by The U.S. Food and Drug Administration.
   
• For instance, in March 2024, Bristol Myers Squibb reported that the FDA approved the Breyanzi as a CAR T-cell therapy for CD19 in patients older than 18 years who have relapsed or relapsed CLL or SLL, with received normal alteration from the FDA at an accelerated rate.
   
• The fast-tracked market availability of CAR T-cell therapies that advance clinical care has grown due to the broad range of accelerated approval strategies provided by the FDA, such as Orphan Drug and Fast Track.
   

The CAR T-cell therapy market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• Notable findings by the government and relevant policy institutions claim that they support the use of advanced technologies such as CAR T-cell therapies in areas such as cancer treatment.
   
• For example, the NHS made a notice that said annually a maximum of 215 adult patients suffering from diffuse large B-cell lymphoma, which could not be cured within a year and would have received more than one targeted treatment, would receive coverage for Yescarta, in 2023's April.
   
• Moreover, Tecartus can now be used in adults of age 26 years and above that are suffering from growing or resistant treatment B-cell acute lymphoblastic leukemia. The aforementioned policies are increasing the patient population for CAR T-cell therapies in the UK creating room for market expansion.
   

Japan CAR T-cell therapy market is anticipated to witness lucrative growth between 2025 – 2034.
 

• There is a high prevalence of cancer amongst the Japanese population, and blood cancer such as leukemia and lymphomas are more common.
   
• According to the estimates made by the National Cancer Center of Japan, there were 1,019,000 new cancer patients and 380,400 dying due to cancer in 2022, which indicates the severity of the issue. The CAR T-cell therapies are effective options in treating these conditions.
   
• The Government of Japan's Ministry of Health has given the green light for several CAR T-cell therapies, which demonstrates Japan's willingness to offer world-class care for its aging population and to address the growing burden of cancer.
   

The CAR T-cell therapy market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• The Kingdom of Saudi Arabia spent substantial money on the healthcare sector due to the Vision 2030 project, which was meant to improve the availability of such complex infusions as CAR T-cell therapies.
   
• Cancer care services are being improved, and it is one of the areas that the government has made a priority, with many of the hospitals now ready to provide complex cancer treatments.
   
• Market growth is also being promoted by patient-focused approaches with CAR T-cell therapies, aids that are helping bring new medications to the market.
   

CAR T-cell Therapy Market Share

The market is competitive and includes both global companies and many smaller companies. A focus on building advanced CAR T-cell therapy technologies such as allogeneic CAR T-cells, combination therapies, or next-generation CAR T-cell receptors seems to be important for the participants. Strategic alliances with research institutions and healthcare providers are necessary for the absorption of the new technologies, to increase the reach to clients and satisfy the growing demand for the CAR T-cell therapy. Furthermore, the support from the government and the simplification of the processes for the approval of new medicines lead to positive changes and to the entry into the market, further strengthening the companies in the expanding market of CAR T-cell therapy.
 

USPs of the CAR T-cell Therapy Market

• Immunotherapy treatments are customized for individual cancer patients.
   
• Clinical trials demonstrate effectiveness against advanced and treatment-resistant cancers.
   
• Ongoing research expands treatment applications and patient access.
   
• Targeted therapeutic approach reduces impact on healthy tissue.
   

CAR T-cell Therapy Market Companies

Some of the eminent market participants operating in the CAR T-cell therapy industry include:

• Allogene Therapeutics
• Autolus Therapeutics
• bluebird bio
• Bristol-Myers Squibb Company
• CRISPR Therapeutics
• Gilead Sciences
• GSK plc.
• ImmunoAct
• Johnson & Johnson
• JW Therapeutics (Shanghai)
• Medigene AG
• Merck KGaA
• Novartis AG
• Sangamo Therapeutics
• Sorrento Therapeutics
   

CAR T-cell Therapy Industry News:

• In February 2024, BioNTech SE and Autolus Therapeutics plc entered a partnership that aimed to jointly develop their autologous CAR-T programs as they sought the necessary approvals from health authorities. Such a partnership allowed BioNTech to broaden the scope of its BNT211 program during cancer trials in a cost-effective manner, giving a wider reach over the cancer therapeutics market.
   
• In January 2024, AbbVie and Umoja Biopharma agreed on two exclusive option and license agreements for the VivoVec platform that allowed for the development of multiple in-situ generated CAR T cell therapy candidates for oncology. According to the first agreement, AbbVie was granted a sole option to license on an exclusive basis the CD19 targeted in-situ CAR T candidates developed by Umoja. The second agreement detailed the development of up to four additional in-situ CAR T candidates with targeting discovery targets that should be selected by AbbVie.
   

The CAR T-cell therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Abecma (idecabtagene vicleucel)
• Breyanzi (lisocabtagene maraleucel)
• Carvykti (ciltacabtagene autoleucel)
• Kymriah (tisagenlecleucel)
• Tecartus (brexucabtagene autoleucel)
• Yescarta (axicabtagene ciloleucel)
• Other products

Market, By Indication

• Leukemia
• Lymphoma
• Multiple myeloma
• Other indications

Market, By Demographic

• Adults
• Pediatric

Market, By End Use

• Hospitals
• Cancer treatment centers
• Specialty clinics

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE